Biotech Giant with 8 Years of Dividend Growth Solidifies Position on Best Dividend Stocks List
Aaron Levitt Sep 25, 2019
When it comes to healthcare and biotech tech stocks, pipeline is everything. It’s here that a biotech stock can make or break it. A strong pipeline can lead to billions in future revenues, move your company from the start-up phase into an elder statesman and keep recurring revenues going for decades. If nothing else, investors in the sector need to focus on this one fact.
Luckily for our Best Dividend Stocks List pick in the sector, its strong pipeline has managed to succeed on every level and has made it one of the best dividend stocks out there.
See our initial pick here.
Early on, our pick’s strong pipeline resulted in an impressive array of leading drugs that still generate billions in revenues for the firm, even today. The best part is that these blockbusters have enabled our pick to not only reward shareholders with increasing dividends and buybacks but have also allowed it to spend heavily on R&D. New forays into advanced oncology medicines, heart therapies and other rare diseases have started to bear serious fruit. These new drugs will be able to power our pick’s cash flows far into the future.
And what it can’t develop – our pick can buy.
Thanks to its abundance of cash flows, our biotech pick has been able to buy out rivals in order to grow its presence further. This includes a recent deal that will add another blockbuster drug to its arsenal and be instantly accretive to revenues. This, in turn, will drive dividends, buybacks, cash flows and its pipeline development even further.
With so many wins under its belt already and the victories continuing to come, our pick has the goods to keep investors happy for decades.
To summarize, here are five reasons why you should own this stock:
- Thanks to its portfolio of blockbuster drugs, our pick pulled in more than $10 billion in sales for the first half of the year alone!
- Since the firm started paying a dividend in 2011, our pick has grown its quarterly payout by well over 400%.
- Smartly used M&A to add additional blockbuster drugs and research to its already huge portfolio.
- Possesses one of the largest medicine pipelines, with numerous oncology and biosimilar drugs in development.
- Healthy payout ratio of 41% and growing yield of 2.95%.
Our Best Dividend Stocks List has 20 of the highest-rated stocks by our proprietary rating system. Go Premium to find out the entire list.
Get Email Updates
Join over 100,000 investors who get the latest news from Dividend.com